
News|Videos|July 3, 2024
Monitoring Patients With Mild/Moderate Multiple Sclerosis
The key opinion leaders provide recommendations on the optimal frequency for evaluating disease progression in patients with mild to moderate MS, emphasizing effective monitoring methods and the most appropriate tools for best clinical practice.
Advertisement
Episodes in this series

How frequently should patients with mild to moderate MS be evaluated for disease activity and progression?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia
2
Overviewing Promising Phase 1/2 Data of Gene Therapy ETX101 in Dravet Syndrome: Joseph Sullivan, MD
3
FDA Action Update, November 2025: Approvals, Clearance, and Boxed Warning
4
Gene Therapy ETX101 Demonstrates Significant Effects on Seizure Reduction, Neurodevelopmental Outcomes in POLARIS Phase 1/2 Program
5



























